CST3 and B-cell non-Hodgkin lymphoma: In their study on 52 patients with B-cell lymphoma (41 aggressive lymphomas and 11 indolent lymphomas), Softić et al. [25] demonstrated a significant reduction of cystatin C levels with disease remission after the third cycle of chemotherapy, and that aggressive lymphomas almost completely contributed to the statistical significance of the complete sample.